Get the Stockscreener App
3.385
0.96%
0.025
Larimar Therapeutics Inc stock is traded at $3.385, with a volume of 730.97K.
It is up +0.96% in the last 24 hours and down -8.32% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$3.36
Open:
$3.36
24h Volume:
730.97K
Relative Volume:
0.42
Market Cap:
$281.26M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-4.0298
EPS:
-0.84
Net Cash Flow:
$-33.46M
1W Performance:
-13.24%
1M Performance:
-8.32%
6M Performance:
+6.01%
1Y Performance:
-14.34%
1-Day Range:
$3.345
$3.455
1-Week Range:
$3.305
$3.94
52-Week Range:
$1.61
$5.37
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.385 | 279.18M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.92 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.55 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.75 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.69 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.75 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
Short Interest in Larimar Therapeutics, Inc. (NASDAQ:LRMR) Decreases By 19.2% - MarketBeat
Why Larimar Therapeutics Inc. stock could rally in 2025Quarterly Portfolio Summary & Safe Entry Trade Reports - moha.gov.vn
Comparing Altimmune (NASDAQ:ALT) & Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar heads to JPMorgan as rare disease program draws investor attention - MSN
Larimar Heads to JPMorgan as Rare Disease Program Draws Investor Attention - MyChesCo
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Should I hold or sell Larimar Therapeutics Inc. stock in 20252025 Sector Review & Smart Money Movement Tracker - Улправда
How buybacks impact Larimar Therapeutics Inc. stock value2025 Major Catalysts & Advanced Technical Analysis Signals - Улправда
Will Larimar Therapeutics Inc. (ZA71) stock see valuation expansionMarket Activity Summary & Advanced Technical Signal Analysis - Улправда
How institutional buying supports Larimar Therapeutics Inc. stockJuly 2025 Update & Reliable Intraday Trade Plans - Улправда
Is Larimar Therapeutics Inc. stock a contrarian buyInsider Buying & Daily Technical Stock Forecast Reports - Улправда
Moving Averages: Can Larimar Therapeutics Inc. stock rebound after recent weakness2025 Earnings Surprises & Accurate Technical Buy Alerts - Улправда
Market Fear: How Larimar Therapeutics Inc. (ZA71) stock correlates with oil marketsJuly 2025 Outlook & Precise Swing Trade Entry Alerts - Улправда
How Larimar Therapeutics Inc. (ZA71) stock correlates with oil marketsJuly 2025 Gainers & Free Expert Approved Momentum Trade Ideas - Улправда
Published on: 2025-12-20 00:54:00 - Улправда
Why Larimar Therapeutics Inc. stock appeals to analysts2025 Stock Rankings & Risk Controlled Stock Alerts - Bölüm Sonu Canavarı
US Market Wrap: Will Larimar Therapeutics Inc. (ZA71) stock see valuation expansionMarket Growth Report & Short-Term Trading Alerts - Улправда
Published on: 2025-12-19 13:18:47 - ulpravda.ru
Published on: 2025-12-19 05:26:13 - Улправда
Is Larimar Therapeutics Inc. (ZA71) stock a buy during volatile marketsPrice Action & Comprehensive Market Scan Insights - Улправда
Why Larimar Therapeutics Inc. stock remains on buy lists2025 Sector Review & Risk Managed Investment Strategies - Улправда
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Why Larimar Therapeutics Inc. stock is recommended by analystsPortfolio Gains Summary & AI Based Buy/Sell Signal Reports - Улправда
Larimar Therapeutics exchanges common stock for preferred shares in agreement with Blue Owl - Investing.com Australia
Larimar Therapeutics exchanges common stock for preferred shares in agreement with Blue Owl By Investing.com - Investing.com South Africa
Larimar Therapeutics Executes Strategic Stock Exchange Agreement - TipRanks
Larimar Therapeutics Earnings Notes - Trefis
Get in on Larimar Therapeutics Inc’s (LRMR) buy-in window today! - setenews.com
Can Larimar Therapeutics Inc. stock sustain market leadership2025 Winners & Losers & Weekly Return Optimization Alerts - Newser
How geopolitical risks impact Larimar Therapeutics Inc. (ZA71) stockMarket Rally & AI Enhanced Execution Alerts - Newser
Top 3 Health Care Stocks That May Rocket Higher In December - Benzinga
How Larimar Therapeutics Inc. (ZA71) stock behaves in tightening cyclesAnalyst Upgrade & Proven Capital Preservation Methods - Newser
Will Larimar Therapeutics Inc. (ZA71) stock recover faster than industry2025 Big Picture & Free AI Powered Buy and Sell Recommendations - Newser
Will Larimar Therapeutics Inc. (ZA71) stock profit from automation wave2025 Trade Ideas & Weekly Watchlist for Hot Stocks - Newser
Top investors say Larimar Therapeutics Inc (LRMR) ticks everything they need - Setenews
Why Larimar Therapeutics Inc. (ZA71) stock stays undervaluedWeekly Trend Recap & Comprehensive Market Scan Insights - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Larimar Therapeutic - The National Law Review
Is Larimar Therapeutics Inc a good long term investmentStock Rotation Strategies & High Return Capital Strategies - earlytimes.in
Short Covering May Lift Piccadily Sugar Allied Industries Limited in Near TermPrice Channel Trading & Small Budget Trading Tips - earlytimes.in
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Will Larimar Therapeutics Inc. stock outperform value stocks2025 Market WrapUp & Weekly Top Gainers Trade List - moha.gov.vn
Published on: 2025-11-27 11:17:59 - moha.gov.vn
Published on: 2025-11-26 23:31:58 - moha.gov.vn
Are Smart Investors Making the Right Decision? Larimar Therapeutics Inc (LRMR) - setenews.com
Larimar Therapeutics Advances Phase 1 Study on Nomlabofusp for Friedreich’s Ataxia - MSN
Should You Track Oswal Yarns Limited as a LongTerm Growth PlayTechnical Analysis Insights & Learn to Trade with Real-Time Feedback - earlytimes.in
Is Larimar Therapeutics Inc. stock a smart buy before Fed meetingForecast Cut & Daily Profit Focused Screening - newser.com
Larimar Therapeutics Highlights Promising Friedreich’s Ataxia Data - MSN
Why Larimar Therapeutics Inc. (ZA71) stock stays on top picksMarket Growth Review & Risk Controlled Swing Alerts - newser.com
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):